The primary objectives of this phase II study are as follows: - To determine the objective response rate of SGN-30 in two study groups patients with HD treated with 6 or 12 mgkg and patients with ALCL treated with 6 or 12 mgkg - To determine the duration of response in patients with HD and in patients with ALCL - To investigate the toxicity profile of SGN-30 at a dose of 6 or 12 mgkg for ALCL or doses of 6 or 12 mgkg for HD
Data and Resources
- A Phase II Multi-Dose Study of SGN-30 anti-CD30 mAb in Patients with Refractory or Recurrent Hodgkins Disease or Anaplastic Large Cell Lymphomajson
The primary objectives of this phase II study are as follows: - To determine...
|Release Date|| |
License Not Specified
|Public Access Level|| |